Insider Transactions Reported | Cidara Therapeutics(CDTX)saw insider trading activity on 6/30/2025

Cidara Therapeutics(CDTX) saw insider trading activity on 6/30/2025, there was 1 insider trade during the day.

【History Insider Transaction】

Declare date	Position	Name	Buy/Sell	Quantity	Price per share/USD	Total Amount/USD
6/30/2025	--	RA CAPITAL MANAGEMENT, L.P.	Buy	2272727	44.00	99999.99k
6/4/2025	--	Mineo Chrysa	Buy	2270	21.71	49.28k
6/4/2025	--	Mineo Chrysa	Buy	1050	23.44	24.61k
3/13/2025	COO & CLO	Ward Shane	Sell	1664	21.96	36.54k
3/13/2025	CHIEF SCIENTIFIC OFFICER	Tari Leslie	Sell	1773	21.96	38.94k
11/29/2024	--	RA CAPITAL MANAGEMENT, L.P.	Buy	389716	14.91	5811.44k
9/13/2024	CHIEF SCIENTIFIC OFFICER	Tari Leslie	Sell	909	11.64	10.58k
9/13/2024	Chief Medical Officer	Sandison Taylor	Sell	924	11.64	10.75k
6/11/2024	President & CEO	Stein Jeffrey	Buy	8000	13.21	105.68k
3/12/2024	COO & CLO	Ward Shane	Sell	20473	0.67	13.71k

[Company Profile]
Cidara Therapeutics, Inc. was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. CD101 is an echinocandin—a proven class of antifungals. The Company's initial proprietary product candidates are formulations of its novel compound, CD101, for the treatment of serious fungal infections. The Company's first product candidate is CD101 intravenous, formerly biafungin, a potential once-weekly intravenous, or IV, therapy being developed for the treatment and prevention of systemic fungal infections. The Company's second product candidate, CD101 topical, formerly topifungin, is a topical formulation of CD101 for the treatment of vulvovaginal candidiasis, or VVC, a prevalent mucosal infection. CD101 topical is the first topical application of the echinocandin class of antifungals. In addition, The Company has developed a proprietary immunotherapy technology platform, CloudbreakTM, which it use to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. The Company is developing its first Cloudbreak development candidate, C001, for the treatment of invasive aspergillosis, an infection caused by the fungal pathogen, Aspergillus. The Company is also evaluating additional opportunities to expand its Cloudbreak immunotherapy platform to other areas of infectious disease.